Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nalbuphine + magnesium sulfate is a combination of two agents commonly used as adjuvants in anesthesia and pain management, particularly in perioperative and obstetric settings. Nalbuphine is a synthetic opioid analgesic with mixed agonist-antagonist activity—acting as an agonist at kappa opioid receptors and an antagonist at mu opioid receptors—providing potent analgesia with a ceiling effect on respiratory depression. Magnesium sulfate, an inorganic salt, acts primarily as an NMDA receptor antagonist and has been shown to enhance the efficacy of other analgesics while providing additional benefits such as reducing shivering during spinal anesthesia. The combination is studied for its ability to improve postoperative pain control, prolong the duration of anesthesia, reduce perioperative shivering, and potentially decrease the need for additional opioids[1][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nalbuphine + magnesium sulfate.